Herantis Pharma – executive interview

Herantis Pharma – executive interview

Herantis Pharma — 2 videos in collection

More on this equity

In this interview, we speak to Antti Vuolanto, CEO of Herantis Pharma. We discuss the company’s recently announced clinical data from its Phase Ib trial in Parkison’s disease patients, what to expect from the upcoming biomarker data and the next steps for Herantis’s lead programme HER-096, a peptide therapeutic.

Herantis Pharma is a Finland-based clinical-stage biotechnology company focused on developing disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases.


You may also be interested in these:

Healthcare

Herantis Pharma – executive interview